GYRE 10-Q: SEC filing
Gyre Therapeutics
Filed with the SEC on · accession 0001193125-26-450334
GYRE filed a 10-Q (quarterly report) with the SEC on Nov 6, 2026. Gyre Therapeutics filed its quarterly 10-Q report for Q3 2026, disclosing financial results including revenue, expenses, and a merger with Cullgen.
Summary of the filing
Gyre Therapeutics filed its quarterly 10-Q report for Q3 2026, disclosing financial results including revenue, expenses, and a merger with Cullgen. The filing also notes the NDA for hydronidone passed NMPA review and inspection.
Key details
✦ Ask GOAX AI about this filing — what it means for GYRE, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for GYRE?
Click hereFrequently asked questions
What did GYRE file with the SEC on Nov 6, 2026?
GYRE filed a 10-Q (SEC filing). Gyre Therapeutics filed its quarterly 10-Q report for Q3 2026, disclosing financial results including revenue, expenses, and a merger with Cullgen. The filing also notes the NDA for hydronidone passed NMPA review and inspection.
How do I read a 10-Q?
The quarterly report: unaudited results for the quarter plus management’s comments. Compare revenue, margins and cash flow with the same quarter last year. Check MD&A for guidance changes and what drove the quarter.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 10-Q (quarterly report): The quarterly report: unaudited results for the quarter plus management’s comments.
Other GYRE SEC filings
Get alerts when GYRE files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days